Pavithra Viswanath, PhD

Associate Professor
Associate Adjunct Professor

Biography

Dr. Pavithra Viswanath is an Associate Professor in the Department of Radiology and Biomedical Imaging at UCSF. She graduated with a Ph D in Biochemistry from the Indian Institute of Science in Bangalore, India. The overall vision of her research is to harness insights from tumor genetics, epigenetics and biology to drive the preclinical development of novel, metabolic imaging biomarkers that will ultimately benefit patients by enabling the non-invasive assessment of tumor burden and response to therapy. In parallel, she will pinpoint metabolic vulnerabilities that can be exploited for the development of novel therapeutic and theranostic agents. Her long-term goal is to work with clinical and translational colleagues at UCSF and beyond to enable clinical translation of the imaging methods, therapeutics and theranostics that come out of her preclinical studies.

Education

2020 - Diversity, Equity, and Inclusion Champion Training, University of California San Francisco
PhD, 08/2007 - Biochemistry, Indian Institute of Science
MS, 08/2003 - Biochemistry, Indian Institute of Science
BS, 08/2000 - Microbiology, St. Xavier's college

Honors and Awards

Margaret Hart Surbeck Travel Award, Dept. of Radiology and Biomedical Imaging, UCSF, 2019
Inaugural Women in Neuro-oncology Basic/Translational Science Research Award, Society for Neuro-oncology, 2019
Career Enhancement Program Award, UCSF Brain Tumor Center, 2018-2019
Career Enhancement Program Award, UCSF Brain Tumor Center, 2017-2018

Publications

Viswanath P, Batsios G, Mukherjee J, Gillespie AM, Larson PEZ, Luchman HA, Phillips JJ, Costello JF, Pieper RO, Ronen SM. Non-invasive assessment of telomere maintenance mechanisms in brain tumors. Nat Commun. 2021 01 04; 12(1):92.
Zhao N, Huang Y, Wang YH, Muir RK, Chen YC, Hooshdaran N, Wei J, Viswanath P, Seo Y, Ruggero D, Renslo AR, Evans MJ. Ferronostics: Measuring Tumoral Ferrous Iron with PET to Predict Sensitivity to Iron-Targeted Cancer Therapies. J Nucl Med. 2020 Nov 27.
Subramani E, Radoul M, Najac C, Batsios G, Molloy AR, Hong D, Gillespie AM, Santos RD, Viswanath P, Costello JF, Pieper RO, Ronen SM. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. Cancer Res. 2020 11 15; 80(22):5098-5108.
MR-detectable metabolic biomarkers of response to mutant IDH inhibition in low-grade glioma. Theranostics. 2020; 10(19):8757-8770.
Batsios G, Najac C, Cao P, Viswanath P, Subramani E, Saito Y, Gillespie AM, Yoshihara HAI, Larson P, Sando S, Ronen SM. In vivo detection of ?-glutamyl-transferase up-regulation in glioma using hyperpolarized ?-glutamyl-[1-13C]glycine. Sci Rep. 2020 04 10; 10(1):6244.
Batsios G, Viswanath P, Subramani E, Najac C, Gillespie AM, Santos RD, Molloy AR, Pieper RO, Ronen SM. PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival. Sci Rep. 2019 07 19; 9(1):10521.
Najac C, Radoul M, Le Page LM, Batsios G, Subramani E, Viswanath P, Gillespie AM, Ronen SM. In vivo investigation of hyperpolarized [1,3-13C2]acetoacetate as a metabolic probe in normal brain and in glioma. Sci Rep. 2019 03 04; 9(1):3402.
Radoul M, Najac C, Viswanath P, Mukherjee J, Kelly M, Gillespie AM, Chaumeil MM, Eriksson P, Delos Santos R, Pieper RO, Ronen SM. HDAC inhibition in glioblastoma monitored by hyperpolarized 13 C MRSI. NMR Biomed. 2019 02; 32(2):e4044.
Viswanath P, Radoul M, Izquierdo-Garcia JL, Luchman HA, Gregory Cairncross J, Pieper RO, Phillips JJ, Ronen SM. Mutant IDH1 gliomas downregulate phosphocholine and phosphoethanolamine synthesis in a 2-hydroxyglutarate-dependent manner. Cancer Metab. 2018; 6:3.
2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. Cancer Res. 2018 05 01; 78(9):2290-2304.
Mazor T, Chesnelong C, Pankov A, Jalbert LE, Hong C, Hayes J, Smirnov IV, Marshall R, Souza CF, Shen Y, Viswanath P, Noushmehr H, Ronen SM, Jones SJM, Marra MA, Cairncross JG, Perry A, Nelson SJ, Chang SM, Bollen AW, Molinaro AM, Bengtsson H, Olshen AB, Weiss S, Phillips JJ, Luchman HA, Costello JF. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):10743-10748.
Development of a rapid and reliable assay for in vitro determination of compound cidality against the asexual stages of Plasmodium falciparum. Acta Parasitol. 2016 Dec 01; 61(4):828-835.
Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 11 15; 76(22):6680-6689.
Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis. Mol Cancer Res. 2016 10; 14(10):976-983.
Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring. Neuroimage Clin. 2016; 12:180-9.
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters. Oncotarget. 2016 Jun 07; 7(23):34942-55.
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells. Front Oncol. 2016; 6:60.
Metabolic reprogramming of pyruvate dehydrogenase is essential for the proliferation of glioma cells expressing mutant IDH1. Mol Cell Oncol. 2016 Apr 01; 3(2):e1077922.
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. Cancer Res. 2015 Aug 01; 75(15):2999-3009.
Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nat Commun. 2015 Mar 31; 6:6715.
Metabolic reprogramming in mutant IDH1 glioma cells. PLoS One. 2015; 10(2):e0118781.
Aminoazabenzimidazoles, a novel class of orally active antimalarial agents. J Med Chem. 2014 Jul 10; 57(13):5702-13.
Repositioning: the fast track to new anti-malarial medicines? Malar J. 2014 Apr 14; 13:143.